Factor VIIa

Platelets

Volumn , Issue , 2013, Pages 1257-1274

  Man Chiu, Poon ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882566378     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00061-4     Document Type: Chapter

References (173)

1. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42(8):975-979.
2. Brecher M.E., Hay S.N. Bacterial contamination of blood components. Clin Microbiol Rev 2005, 18(1):195-204.
3. Fuller A.K., Uglik K.M., Savage W.J., Ness P.M., King K.E. Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single-donor platelets. Transfusion 2009, 49(12):2588-2593.
4. Hedner U., Glazer S., Pingel K., Alberts K.A., Blomback M., Schulman S., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988, 2(8621):1193.
5. Hay C.R., Negrier C., Ludlam C.A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997, 78(6):1463-1467.
6. Lusher J.M., Roberts H.R., Davignon G., Joist J.H., Smith H., Shapiro A., et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998, 4(6):790-798.
7. Key N.S., Aledort L.M., Beardsley D., Cooper H.A., Davignon G., Ewenstein B.M., et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998, 80(6):912-918.
8. Shapiro A.D., Gilchrist G.S., Hoots W.K., Cooper H.A., Gastineau D.A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998, 80(5):773-778.
9. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004, 2(6):899-909.
10. Morrissey J.H., Mutch N.J. Tissue factor structure and function. Hemostasis and Thrombosis. Basic Principles and Clinical Practice 2006, 91-106. Lippincott Williams & Wilkins, Philadelphia. 5th ed. R.W. Colman, V.J. Marder, A.W. Clowes, J.N. George, S.Z. Goldhaber (Eds.).
11. Geczy C.L. Cellular mechanisms for the activation of blood coagulation. Int Rev Cytol 1994, 152:49-108.
12. Camerer E., Lolsto A.B., Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996, 81:1-41.
13. Giesen P.L., Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000, 26(4):379-384.
14. Todoroki H., Nakamura S., Higure A., Okamoto K., Takeda S., Nagata N., et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000, 127(2):209-216.
15. Giesen P.L., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J.T., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999, 96(5):2311-2315.
16. Jurlander B., Thim L., Klausen N.K., Persson E., Kjalke M., Rexen P., et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001, 27(4):373-384.
17. Lindley C.M., Sawyer W.T., Macik B.G., Lusher J., Harrison J.F., Baird-Cox K., et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994, 55(6):638-648.
18. Agersø H., Brophy D.F., Pelzer H., Martin E.J., Carr M., Hedner U., et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011, 9(2):333-338.
19. Villar A., Aronis S., Morfini M., Santagostino E., Auerswald G., Thomsen H.F., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10(4):352-359.
20. Berrettini M., Mariani G., Schiavoni M., Rocino A., Di Paolantonio T., Longo G., et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001, 86(6):640-645.
21. Seested T., Appa R.S., Christensen E.I., Ioannou Y.A., Krogh T.N., Karpf D.M., et al. In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver. Thromb Res 2011, 127(4):356-362.
22. Gopalakrishnan R., Hedner U., Ghosh S., Nayak R.C., Allen T.C., Pendurthi U.R., et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010, 8(2):301-310.
23. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5(9):1904-1913.
24. Ghosh S., Pendurthi U.R., Steinoe A., Esmon C.T., Rao L.V. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007, 282(16):11849-11857.
25. Lopez-Vilchez I., Hedner U., Altisent C., Diaz-Ricart M., Escolar G., Galan A.M. Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011, 178(6):2938-2948.
26. Diness V., Bregengaard C., Erhardtsen E., Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992, 67(2):233-241.
27. Turecek P.L., Richter G., Muchitsch E.M., Pichler L., Schwarz H.P., Morrissey J. Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model. Thromb Haemost 1997, 78(Suppl.):222.
28. Hedner U., Bergqvist D., Ljungberg J., Nilsson B. Haemostatic effect of factor VIIa in thrombocytopenic rabbits. Blood 1985, 86(Suppl. 1):1043.
29. Tranholm M., Rojkjaer R., Pyke C., Kristensen A.T., Klitgaard B., Lollike K., et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res 2003, 109(4):217-223.
30. Kristensen J., Killander A., Hippe E., Helleberg C., Ellegard J., Holm M., et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996, 26(Suppl. 1):159-164.
31. Brenner B., Hoffman R., Balashov D., Shutluko E., Culic S.D., Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005, 11(4):401-410.
32. Poon M.C. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?. Curr Hematol Rep 2003, 2(2):139-147.
33. Gerotziafas G.T., Zervas C., Gavrielidis G., Tokmaktsis A., Hatjiharissi E., Papaioannou M., et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002, 69(3):219-222.
34. Waddington D.P., McAuley F.T., Hanley J.P., Summerfield G.P. The use of recombinant factor VIIa in a Jehovah's Witness with auto-immune thrombocytopenia and post-splenectomy haemorhage. Br J Haematol 2002, 119:286-288.
35. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003, 120(5):909-910.
36. Virchis A., Hughes C., Berney S. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia. Hematol J 2004, 5(3):281-282.
37. Busani S., Marietta M., Pasetto A., Girardis M. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005, 93(2):381-382.
38. Barnes C., Blanchette V., Canning P., Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005, 15(2):145-150.
39. Baxter M.S., Schroeder W.S., Cheng Y., Bernstein Z.P. Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Ann Pharmacother 2006, 40(11):2053-2058.
40. Dimitrova V., Atanasova M., Tsankova M., Chernev T., Georgiev S. Autoimmune thrombocytopenia during pregnancy (case report and review of literature). Akush Ginekol (Sofiia) 2007, 46(9):50-55.
41. Salama A., Rieke M., Kiesewetter H., von Depka D.M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol 2009, 88(1):11-15.
42. Vidarsson B., Onundarson P.T. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000, 83(4):634-635.
43. Hoffman R., Eliakim R., Zuckerman T., Rowe J.M., Brenner B. Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia. J Thromb Haemost 2003, 1(3):606-608.
44. Culligan D.J., Salamat A., Tait J., Westland G., Watson H.G. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplant 2003, 31(12):1183-1184.
45. De Fabritiis P., Dentamaro T., Picardi A., Cudillo L., Masi M., Amadori S. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004, 89(2):243-245.
46. Zulfikar B., Kayran S.M. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004, 15(3):261-263.
47. Osborne W., Bhandari S., Tait R.C., Franklin I.M. Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol 2004, 26(3):229-231.
48. Kurekci A.E., Atay A.A., Okutan V., Yavuz S.T., Ozcan O. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005, 16(2):145-147.
49. Savani B.N., Dunbar C.E., Rick M.E. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006, 81(3):218-219.
50. Erikci A.A., Ozturk A., Sayan O. Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis 2006, 17(4):323-324.
51. Ozcelik T., Ozkocaman V., Ozkalemkas F., Ali R., Altundal Y., Ozkan A., et al. Use of recombinant activated factor VII in a patient with severe thrombocytopenia due to myelodysplastic syndrome with uncontrolled gastrointestinal bleeding. Blood Coagul Fibrinolysis 2007, 18(4):385-386.
52. Pamuk G.E., Tasci M., Ozturk E., Demir M. Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias. Med Oncol 2010, 27(1):16-19.
53. Sokolic V., Bukovic D., Fures R., Zadro M., Scuric I., Colak F., et al. Recombinant factor VIIa (rFVIIa) is effective at massive bleeding after caesarean section-a case report. Coll Antropol 2002, 26(Suppl.):155-157.
54. Zupancic-Salek S., Sokolic V., Viskovic T., Sanjug J., Simic M., Kastelan M. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol 2002, 108(3):162-163.
55. Dart B.W., Cockerham W.T., Torres C., Kipikasa J.H., Maxwell R.A. A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome. J Trauma 2004, 57(1):171-174.
56. Merchant S.H., Mathew P., Vanderjagt T.J., Howdieshell T.R., Crookston K.P. Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet Gynecol 2004, 103(5 Pt 2):1055-1058.
57. Thomas A.E., Plews D.E. Use of recombinant factor VIIa in platelet disorders-a single centre experience. Blood Coagul Fibrinolysis 2001, 12:A14.
58. Heuer L., Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005, 16(4):287-290.
59. Wrobel G., Dobaczewski G., Patkowski D., Sokol A., Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006, 47(5 Suppl.):729-730.
60. Coppola A., Simone C.D., Palmieri N.M., Coppola D., Lanza F., Ruosi C., et al. Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagul Fibrinolysis 2007, 18(2):199-201.
61. Pihusch M., Bacigalupo A., Szer J., von Depka Prondzinki M., Gaspar-Blaudschun B., Hyveled L., et al. Recombinant activated factor VII in treatment of bleeding complication following hematopoietic stem cell transplantation. J Thromb Haemost 2005, 3:1935-1944.
62. Nevo S., Swan V., Enger C., Wojno K.J., Bitton R., Shabooti M., et al. Acute bleeding after bone marrow transplantation (BMT)-incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood 1998, 91(4):1469-1477.
63. Blatt J., Gold S.H., Wiley J.M., Monahan P.E., Cooper H.C., Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001, 28(4):405-407.
64. Phelan J.T., Broder J., Kouides P.A. Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: a case report of bilateral uterine artery embolization. Am J Hematol 2004, 77(2):151-155.
65. Eller P., Pechlaner C., Wiedermann C.J. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding. Thromb J 2006, 4(1):1.
66. Tengborn L., Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost 1996, 75(6):981-982.
67. Poon M.-C., Demers C., Jobin F., Wu J.W. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999, 94(11):3951-3953.
68. Chuansumrit A., Sangkapreecha C., Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999, 82(6):1778.
69. Robinson K.L., Savoia H., Street A.M. Thrombotic complications in two patients receiving NovoSeven. Haemophilia 2000, 6(4):349.
70. d'Oiron R., Menart C., Trzeciak M.C., Nurden P., Fressinaud E., Dreyfus M., et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000, 83(5):644-647.
71. van Buuren H.R., Wielenga J.J. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002, 47(9):2134-2136.
72. Almeida A.M., Khair K., Hann I., Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003, 121(3):477-481.
73. Chuansumrit A., Suwannuraks M., Sri-Udomporn N., Pongtanakul B., Worapongpaiboon S. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003, 14(2):187-190.
74. Caglar K., Cetinkaya A., Aytac S., Gumruk F., Gurgey A. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003, 20(6):435-438.
75. Bell J.A., Savidge G.F. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost 2003, 9(2):167-170.
76. Poon M.C., d'Oiron R., von Depka M., Khair K., Negrier C., Karafoulidou A., et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004, 2(7):1096-1103.
77. Kaleelrahman M., Minford A., Parapia L.A. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004, 125(1):95-96.
78. Kale A., Bayhan G., Yalinkaya A., Yayla M. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med 2004, 32(5):456-458.
79. Uzunlar H.I., Eroglu A., Senel A.C., Bostan H., Erciyes N. A patient with Glanzmann's thrombasthenia for emergent abdominal surgery. Anesth Analg 2004, 99(4):1258-1260.
80. Coppola A., Tufano A., Cimino E., Agangi A., Maruotti G.M., Martinelli P., et al. Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment. Thromb Haemost 2004, 92(6):1450-1452.
81. Yilmaz B.T., Alioglu B., Ozyurek E., Akay H.T., Mercan S., Ozbek N. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005, 26(6):843-845.
82. Hennewig U., Laws H.J., Eisert S., Gobel U. Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VII a. Klin Padiatr 2005, 217(6):365-370.
83. Shamsi T.S., Hossain N., Soomro N., Hasan J.A., Noorani M., Kazi S., et al. Use of recombinant factor VIIa for massive postpartum haemhorrhage: case series and review of literature. J Pak Med Assoc 2005, 55(11):512-515.
84. Bay A., Oner A.F. Glanzmann thrombasthenia successfully operated for nasal deformation with recombinant factor VIIA. Indian Pediatr 2006, 43(12):1094.
85. Inagaki M., Mori T., Tsunematsu Y., Ambo H., Kawai Y. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report. Blood Coagul Fibrinolysis 2006, 17(4):317-322.
86. Lombardo V.T., Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost 2006, 12(1):115-116.
87. Gunaydin B., Ozkose Z., Pezek S. Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy. J Anesth 2007, 21(1):106-107.
88. Bakdash S., Lyons J.M., Bastacky S.I., Pezzone M.A., McGee J.B., Schoen R.E., et al. Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia. Am J Hematol 2008, 83(5):411-415.
89. Erduran E., Aksoy A., Zaman D. The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy. Blood Coagul Fibrinolysis 2009, 20(3):215-217.
90. Lison S., Spannagl M., Heindl B. Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. Blood Coagul Fibrinolysis 2009, 20(5):371-373.
91. Javed A., Ayyub M., Abrar S., Mansoor M., Khan B., Hussain T. Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa. J Ayub Med Coll Abbottabad 2009, 21(2):171-173.
92. Balci Y.I., Karabulut A., Kabukcu S., Sari I., Keskin A. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia. Clin Appl Thromb Hemost 2011, 17(4):320-322.
93. Poon M.-C., di Minno G., Zotz R., d'Oiron R. rFVIIa is as effective as platelets in Glanzmann thrombasthenia (GT) with or without platelet antibodies and/or refractoriness (PA/PR): data from GT Registry (GTR). J Thromb Haemost 2011, 9(Suppl. 2):89-90.
94. Chitlur M., Ewing N., Kraut E.H., Cooper D.L. Recombinant factor VIIa (rFVIIa) use in Glanzmann's thrombasthenia (GT) and other platelet disorders (OPDS): Hemophilia and Thrombosis Research Society (HTRS) Registry data. J Thromb Haemost 2011, 9(Suppl. 2):340.
95. Ozelo M.C., Svirin P., Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005, 84(12):816-822.
96. Tefre K.L., Ingerslev J., Sorensen B. Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 2009, 15(1):281-284.
97. del Pozo Pozo A.I., Jimenez-Yuste V., Villar A., Quintana M., Hernandez-Navarro F. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis 2002, 13(6):551-553.
98. Langendonck L., Appel I.M. Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease. Pediatr Blood Cancer 2005, 44(7):676-678.
99. Fressinaud E., Sigaud-Fiks M., Le Boterff C., Piot B. Use of recombinant factor VIIa (NovoSeven) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. Haemophilia 1998, 4:299.
100. Révész T., Arets B., Bierings M., van den Bos C., Duval E. Recombinant factor VIIa in severe uremic bleeding [letter]. Thromb Haemost 1998, 80(2):353.
101. Cervera J.S., Mena-Duran A.V., Piqueras C.S. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost 2005, 93(2):383-384.
102. Plews D.E., Thomas A.E. Novel uses of recombinant factor VIIa. Blood 1999, 94(Suppl. 1). [10]: 83b.
103. Musso R., Cultrera D., Russo M., Giuffrida G., Venturino L., Ferlito C., et al. Recombinant activated factor VII as haemostatic agent in Glanzmann's thrombasthenia. Thromb Haemost 1999, 82(Suppl.):621.
104. Devecioglu O., Unuvar A., Anak S., Bilge I., Ander H., Ziylan O. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turk J Pediatr 2003, 45(1):64-66.
105. Ito K., Yoshida H., Hatoyama H., Matsumoto H., Ban C., Mori T., et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 1991, 61(1):40-46.
106. Martin I., Kriaa F., Proulle V., Guillet B., Kaplan C., d'Oiron R., et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002, 119:991-997.
107. Poon M.C., Zotz R., DiMinno G., Abrams Z.S., Knudsen J.B., Laurian Y. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006, 43(Suppl. 1):S33-S36.
108. Meijer K., Sieders E., Slooff M.J., de Wolf J.T., van der Meer J. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII [letter]. Thromb Haemost 1998, 80(1):204-205.
109. Vucelic D., Sabljak P., Pesko P., Stojakov D., Keramatollah E., Nenadic B., et al. The use of recombinant activated factor VII in the treatment of gastrointestinal bleeding following acetylsalicylic acid therapy in a surgical patient. Srp Arh Celok Lek 2008, 136(Suppl. 3):240-245.
110. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004, 2(10):1700-1708.
111. Baudo F., Redaelli R., Caimi T.M., Mostarda G., Somaini G., de Cataldo F. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000, 99(1):21-24.
112. Stein S.F., Duncan A., Cutler D., Glazer S. Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor. Blood 1990, 76(Suppl. 1):438a.
113. Sallah S., Isaksen M., Seremetis S., Payne R.L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-a rebuttal. J Thromb Haemost 2005, 3(4):820-822.
114. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295(3):293-308.
115. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352(8):777-785.
116. Diringer M.N., Skolnick B.E., Mayer S.A., Steiner T., Davis S.M., Brun N.C., et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010, 41(1):48-53.
117. Bruckner B.A., DiBardino D.J., Ning Q., Adeboygeun A., Mahmoud K., Valdes J., et al. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII. J Heart Lung Transplant 2009, 28(8):785-790.
118. Apostolidou I., Sweeney M.F., Missov E., Joyce L.D., John R., Prielipp R.C. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg 2008, 106(2):404-408.
119. van't Veer C., Golden N.J., Mann K.G. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000, 95(4):1330-1335.
120. Butenas S., Brummel K.E., Branda R.F., Paradis S.G., Mann K.G. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002, 99(3):923-930.
121. Monroe D.M., Hoffman M., Oliver J.A., Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997, 99(3):542-547.
122. Butenas S., Brummel K.E., Bouchard B.A., Mann K.G. How factor VIIa works in hemophilia. J Thromb Haemost 2003, 1(6):1158-1160.
123. He S., Blomback M., Jacobsson E.G., Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003, 1(6):1215-1219.
124. Lisman T., Mosnier L.O., Lambert T., Mauser-Bunschoten E.P., Meijers J.C., Nieuwenhuis H.K., et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002, 99(1):175-179.
125. He S., Ekman G.J., Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005, 3(2):272-279.
126. Kjalke M., Ezban M., Monroe D.M., Hoffman M., Roberts H.R., Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001, 114(1):114-120.
127. Galán A.M., Tonda R., Pino M., Reverter J.C., Ordinas A., Escolar G. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003, 43(7):885-892.
128. Lisman T., Adelmeijer J., Cauwenberghs S., Van Pampus E.C., Heemskerk J.W., De Groot P.G. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005, 3(4):742-751.
129. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis.". J Clin Invest 1996, 98(3):863-874.
130. Lisman T., Moschatsis S., Adelmeijer J., Nieuwenhuis H.K., de Groot P.G. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003, 101(5):1864-1870.
131. Niewiarowski S., Levy-Toledano S., Caen J.P. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res 1981, 23:457-463.
132. McGregor L., Hanss M., Sayegh A., Calvette J.J., Trzeciak M.C., Ville D., et al. Aggregation to thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking glycoproteins IIb and IIIa. Thromb Haemost 1989, 62(3):962-967.
133. Osdoit S., Rosa J.-P. Polymeric fibrin interacts with platelets independently from integrin αΙΙbβ3. Blood 2001, 98(Suppl.):518a.
134. Lisman T., Adelmeijer J., Heijnen H.F., de Groot P.G. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004, 103(5):1720-1727.
135. Soslau G., Class R., Morgan D.A., Foster C., Lord S.T., Marchese P., et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 2001, 276(24):21173-21183.
136. Plesner B., Westh P., Nielsen A.D. Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa. Int J Pharm 2011, 406(1-2):62-68.
137. Weimer T., Wormsbacher W., Kronthaler U., Lang W., Liebing U., Schulte S. Prolonged in vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008, 99(4):659-667.
138. Zollner S., Weimer T., Schmidbauer S., Raquet E., Mueller-Cohrs J., Schulte S. Pharmacokinetics of a recombinant albumin-fused, human coagulation factor VIIa (rVIIa-FP) exhibiting prolonged serum half-life in different animal species. Haemophilia 2010, 16(Suppl. 4):33.
139. Salas J., Liu T., Kistanova E., Ashworth T., Slein M., Patel R., et al. Enhanced pharmacokinetics of factor VIIa as a monomeric Fc fusion. J Thromb Haemost 2011, 9(Suppl. 2):268.
140. Sen P., Ghosh S., Ezban M., Pendurthi U.R., Vijaya Mohan R.L. Effect of glycoPEGylation on factor VIIa binding and internalization. Haemophilia 2010, 16(2):339-348.
141. Karpf D.M., Sorensen B.B., Hermit M.B., Holmberg H.L., Tranholm M., Bysted B.V., et al. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011, 128(2):191-195.
142. PegFVIIa.<>,last accessed: August 10,2011. http://www.clinicaltrials.gov/ct2/results?term=Long+Acting-rFVIIa.
143. Moss J., Rosholm A., Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011, 9(7):1368-1374.
144. Moss J., Stenmo C., Jimenez-Yuste V., Bottcher S., Fernandez I. Long-acting glycopegylated recombinant activated factor VII (LA-rFVIIa) is safe and shows a prolonged FVIIa half-life after single and multiple administrations in hemophilia A and B patients, making it suitable for development as prophylactic treatment of patients with hemophilia and inhibitors. Haemophilia 2010, 16(Suppl. 4):31.
145. Chaudhury C., Mehnaz S., Robinson J.M., Hayton W.L., Pearl D.K., Roopenian D.C., et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003, 197(3):315-322.
146. Anderson C.L., Chaudhury C., Kim J., Bronson C.L., Wani M.A., Mohanty S. Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006, 27(7):343-348.
147. Dickneite G., Zoller S., Weimer T., Schmidbauer S., Raquiet E., Mueller-Cohrs J., et al. Prolonged serum half-life of a recombinant fusion protein linking activated coagulation factor VII with albumin (rVIIa-FP) in different preclinical species. J Thromb Haemost 2011, 9(Suppl. 2):385-386.
148. Petrovan R.J., Ruf W. Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem 2001, 276(9):6616-6620.
149. Persson E., Kjalke M., Olsen O.H. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 2001, 98(24):13583-13588.
150. Persson E., Olsen O.H. Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. Eur J Biochem 2002, 269(23):5950-5955.
151. Petrovan R.J., Ruf W. Role of zymogenicity-determining residues of coagulation factor VII/VIIa in cofactor interaction and macromolecular substrate recognition. Biochemistry 2002, 41(30):9302-9309.
152. Persson E., Bak H., Ostergaard A., Olsen O.H. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J 2004, 379(Pt 2):497-503.
153. Soejima K., Mizuguchi J., Yuguchi M., Nakagaki T., Higashi S., Iwanaga S. Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property. J Biol Chem 2001, 276(20):17229-17235.
154. Soejima K., Yuguchi M., Mizuguchi J., Tomokiyo K., Nakashima T., Nakagaki T., et al. The 99 and 170 loop-modified factor VIIa mutants
155. Tranholm M., Kristensen K., Kristensen A.T., Pyke C., Rojkjaer R., Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003, 102(10):3165-3220.
156. Lauritzen B., Tranholm M., Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009, 7(4):651-657.
157. Holmberg H.L., Lauritzen B., Tranholm M., Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009, 7(9):1517-1522.
158. Ghosh S., Ezban M., Persson E., Pendurthi U., Hedner U., Rao L.V. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007, 5(2):336-346.
159. Allen G.A., Persson E., Campbell R.A., Ezban M., Hedner U., Wolberg A.S. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007, 27(3):683-689.
160. Hoffman M., Volovyk Z., Persson E., Gabriel D.A., Ezban M., Monroe D.M. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost 2011, 9(4):759-766.
161. Hoffman M., Persson E., Ezban M., Monroe D.M. Enhanced platelet binding of a rFVIIa analogue (vatreptacog alfa activated) with enhanced tissue factor-independent activity. J Thromb Haemost 2011, 9(Suppl. 2):760-761.
162. Sorensen B., Persson E., Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007, 137(2):158-165.
163. Brophy D.F., Martin E.J., Nolte M.E., Kuhn J.G., Carr M.E. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007, 13(5):533-541.
164. Larsen O.H., Clausen N., Persson E., Ezban M., Ingerslev J., Sorensen B. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. Br J Haematol 2009, 144(1):99-106.
165. Rea C.J., Ezban M., Foley J.H., Sorensen B. rFVIIa-analogue and rFVIIa enhance clot stability more than FVIII in haemophilia. J Thromb Haemost 2011, 9(Suppl. 2):466.
166. Gray L.D., Hussey M.A., Larson B.M., Machlus K.R., Campbell R.A., Koch G., et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res 2011, 128(6):570-576.
167. <>, last accessed August 10,2011. http://www.clinicaltrials.gov/ct2/results?term=nn1731.
168. tm 1, a phase 2 trial investigating the use of rFVIIa analogue (vatreptacog alfa activated) in congenital haemophilia patients with inhibitors. J Thromb Haemost 2011, 9(Suppl. 2):297.
169. Sim D.S., Kellnberger M., Gu J.-M., Bornaes C., Kragh M., Clausen S.K., et al. A novel recombinant factor VIIa variant has a significantly higher therapeutic index than eptacog alfa (activated) in rabbit bleeding and thrombosis models. J Thromb Haemost 2011, 9(Suppl. 2):297.
170. Sim D.S., Mallair C., Liu P., Loomis C., Koellnberger M., Murphy J.E., et al. Bay86-6150, a novel recombinant factor VIIa variant, has a higher therapeutic index than wildtype rFVIIa in murine hemophilia thrombosis and bleeding models. J Thromb Haemost 2011, 9(Suppl. 2):246.
171. Pan J., Kim J., Blank E., Zhang X., Liu T., Wu J., et al. Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7. J Thromb Haemost 2009, 7(Suppl. 2):223.
172. Pan J., Kim J.-Y., Myles T., Blank E., Murphy J.E., Haaning J. Soluble tissue factor-based FVIIa assay for Bay 86-6150, a recombinant FVIIa variant in clinical development. J Thromb Haemost 2011, 9(Suppl. 2):380.
173. Mahlangu J., Coetzee M., Laffan M., Windyga J., Phase I. randomized, double-blind, placebo-controlled, single dose escalation study of the rFVIIa variant (Bay 86-6150) in haemophilia or B with or without inhibitors. Haemophilia 2010, 16(Suppl. 4):31.